Eli Lilly and Company (NYSE: LLY) announced today that it plans to build a new $6.5 billion manufacturing facility at ...

The Indian Active Pharmaceutical Ingredients (API) market, valued at INR 1.07 trillion in 2023, is set to reach INR 1.82 trillion by 2030, growing at a CAGR of ~8.26%. As a leading generics supplier, ...

A recent executive order signed by President Donald Trump calls for the government to build a Strategic Active Pharmaceutical Ingredients Reserve ...

The Houston facility has been selected as one that will make orforglipron, Lilly's new oral GLP-1 agonist for weight-loss, ...

From Washington's vantage point, a full-fledged tariff on patented and branded products is meant to boost domestic ...

Trump said branded pharmaceutical products would face 100 percent tariffs unless certain exemptions applied, sparking some ...

Mumbai: Indoco Remedies Limited has announced that the United States Food and Drug Administration (USFDA) successfully ...

As per the ratings agency, the API capacities are largely fungible in nature and domestic companies might be able to switch ...

Turkish salt manufacturer Safir Tuz aims to reduce foreign dependence in the salt industry with its next-generation active pharmaceutical ingredient (API) production plant in the central Turkish ...

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, ...

Ind-Ra says Indian API makers stabilise profitability on cheaper inputs and portfolio shift, but imports and new PLI ...

Indoco’s API facility at Patalganga completes US FDA inspection with zero observations: Our Bureau, Bengaluru Friday, September 19, 2025, 16:25 Hrs [IST] Indoco Remedies, a full ...